Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are now currently the first-line treatment endorsed by worldwide and national guidelines for patients with Type 2 Diabetes Mellitus (T2DM) who have heart failure, Atherosclerotic Cardiovascular Disease (ASCVD), a high-risk of ASCVD, and Chronic Kidney Disease (CKD).1–4 Apart from that, SGLT2is are also recommended for T2DM patients who are prone to hypoglycemia and are overweight or obese.5 At present, the SGLT2is available in Indonesia are dapagliflozin and empagliflozin, which were launched in 2016 and 2017, respectively.6–9. Here, SLC5A2 is linked to atherosclerosis.